Cétirizine 1 % + minoxidil 5 %

and great increase = excellent. Group 1 showed excellent response in 16 patients, very good in 7, good in 2 and no change in one patient, while in group 2, 17 patients showed excellent response, 6 were very good, 4 were good and one patient showed no change. Fisher’s exact showed statistically insignificant difference between groups.

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Table 2: Changes in clinical and patient‑reported outcomes after 16 weeks of treatment Variable Monotherapy Adjunctive P therapy Hair density score 0.65±0.61 0.68±0.6 0.987 Hair diameter score 1.29±0.59 1.39±0.62 0.628 Standard photography score 1±0.68 1.06±0.57 0.697 Patient satisfaction score 1.13±0.85 1.82±1.07 0.004

Mokhtari F, Faghihi G, Maleki S et al.. Clinical Outcomes of Adding Topical Cetirizine to Minoxidil Therapy in Patients with Androgenetic Alopeci.. J Res Pharm Pract 2026, DOI 10.4103/jrpp.jrpp_22_26. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2: Changes in clinical and patient‑reported outcomes after 16 weeks of treatment Variable Monotherapy Adjunctive P therapy Hair density score 0.65±0.61 0.68±0.6 0.987 Hair diameter score 1.29±0.59 1.39±0.62 0.628 Standard photography score 1±0.68 1.06±0.57 0.697 Patient satisfaction score 1.13±0.85 1.82±1.07 0.004

Mokhtari F, Faghihi G, Maleki S et al.. Clinical Outcomes of Adding Topical Cetirizine to Minoxidil Therapy in Patients with Androgenetic Alopeci.. J Res Pharm Pract 2026, DOI 10.4103/jrpp.jrpp_22_26. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The reported side effects were itching, dry hair, initial hair loss and dandruff which are known side effects of minoxidil and the patients did not complain of any side effects after cetirizine application. There was no significant difference between groups in the number of patients with side effects (P > 0.05).

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.